Hydroxyurea fails to improve the results of MBD chemotherapy in cancer of the head and neck, but reduces toxicity

Steven E. Vogl, Fernando J. Camacho, Barry H. Kaplan, Harvey Lerner, James Cinberg

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Thirty‐six patients with advanced squamous cancer of the head and neck received chemotherapy with hydroxyurea, 2 g/m2 orally two of three weeks, plus methotrexate, bleomycin, and cisplatin (MBD) on a previously established schedule. Nineteen patients had objective responses, including six complete remissions. Eight of 13 patients with regional disease without prior radiation responded, as did 1 of 3 with distant metastases without prior radiation, and 10 of 20 with recurrent disease after radiotherapy. The median duration of response in those with recurrent or metastatic tumor was 6 months, and median survival was 6.5 months. These results are no better than those previously achieved without the addition of hydroxyurea. Toxicity, however, was milder than had previously been observed with MBD, suggesting that higher doses or more intensive schedules of hydroxyurea could be safely administered together with the other three drugs. Cancer 52:2011‐2016, 1983.

Original languageEnglish (US)
Pages (from-to)2011-2016
Number of pages6
JournalCancer
Volume52
Issue number11
DOIs
StatePublished - Jan 1 1983
Externally publishedYes

Fingerprint

Hydroxyurea
Head and Neck Neoplasms
Drug Therapy
Appointments and Schedules
Radiation
Bleomycin
Methotrexate
Cisplatin
Neoplasms
Radiotherapy
Neoplasm Metastasis
Survival
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Hydroxyurea fails to improve the results of MBD chemotherapy in cancer of the head and neck, but reduces toxicity. / Vogl, Steven E.; Camacho, Fernando J.; Kaplan, Barry H.; Lerner, Harvey; Cinberg, James.

In: Cancer, Vol. 52, No. 11, 01.01.1983, p. 2011-2016.

Research output: Contribution to journalArticle

Vogl, Steven E. ; Camacho, Fernando J. ; Kaplan, Barry H. ; Lerner, Harvey ; Cinberg, James. / Hydroxyurea fails to improve the results of MBD chemotherapy in cancer of the head and neck, but reduces toxicity. In: Cancer. 1983 ; Vol. 52, No. 11. pp. 2011-2016.
@article{35f2e0cbb7a54dfc82868984957b09ca,
title = "Hydroxyurea fails to improve the results of MBD chemotherapy in cancer of the head and neck, but reduces toxicity",
abstract = "Thirty‐six patients with advanced squamous cancer of the head and neck received chemotherapy with hydroxyurea, 2 g/m2 orally two of three weeks, plus methotrexate, bleomycin, and cisplatin (MBD) on a previously established schedule. Nineteen patients had objective responses, including six complete remissions. Eight of 13 patients with regional disease without prior radiation responded, as did 1 of 3 with distant metastases without prior radiation, and 10 of 20 with recurrent disease after radiotherapy. The median duration of response in those with recurrent or metastatic tumor was 6 months, and median survival was 6.5 months. These results are no better than those previously achieved without the addition of hydroxyurea. Toxicity, however, was milder than had previously been observed with MBD, suggesting that higher doses or more intensive schedules of hydroxyurea could be safely administered together with the other three drugs. Cancer 52:2011‐2016, 1983.",
author = "Vogl, {Steven E.} and Camacho, {Fernando J.} and Kaplan, {Barry H.} and Harvey Lerner and James Cinberg",
year = "1983",
month = "1",
day = "1",
doi = "10.1002/1097-0142(19831201)52:11<2011::AID-CNCR2820521107>3.0.CO;2-6",
language = "English (US)",
volume = "52",
pages = "2011--2016",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

TY - JOUR

T1 - Hydroxyurea fails to improve the results of MBD chemotherapy in cancer of the head and neck, but reduces toxicity

AU - Vogl, Steven E.

AU - Camacho, Fernando J.

AU - Kaplan, Barry H.

AU - Lerner, Harvey

AU - Cinberg, James

PY - 1983/1/1

Y1 - 1983/1/1

N2 - Thirty‐six patients with advanced squamous cancer of the head and neck received chemotherapy with hydroxyurea, 2 g/m2 orally two of three weeks, plus methotrexate, bleomycin, and cisplatin (MBD) on a previously established schedule. Nineteen patients had objective responses, including six complete remissions. Eight of 13 patients with regional disease without prior radiation responded, as did 1 of 3 with distant metastases without prior radiation, and 10 of 20 with recurrent disease after radiotherapy. The median duration of response in those with recurrent or metastatic tumor was 6 months, and median survival was 6.5 months. These results are no better than those previously achieved without the addition of hydroxyurea. Toxicity, however, was milder than had previously been observed with MBD, suggesting that higher doses or more intensive schedules of hydroxyurea could be safely administered together with the other three drugs. Cancer 52:2011‐2016, 1983.

AB - Thirty‐six patients with advanced squamous cancer of the head and neck received chemotherapy with hydroxyurea, 2 g/m2 orally two of three weeks, plus methotrexate, bleomycin, and cisplatin (MBD) on a previously established schedule. Nineteen patients had objective responses, including six complete remissions. Eight of 13 patients with regional disease without prior radiation responded, as did 1 of 3 with distant metastases without prior radiation, and 10 of 20 with recurrent disease after radiotherapy. The median duration of response in those with recurrent or metastatic tumor was 6 months, and median survival was 6.5 months. These results are no better than those previously achieved without the addition of hydroxyurea. Toxicity, however, was milder than had previously been observed with MBD, suggesting that higher doses or more intensive schedules of hydroxyurea could be safely administered together with the other three drugs. Cancer 52:2011‐2016, 1983.

UR - http://www.scopus.com/inward/record.url?scp=0021042932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021042932&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19831201)52:11<2011::AID-CNCR2820521107>3.0.CO;2-6

DO - 10.1002/1097-0142(19831201)52:11<2011::AID-CNCR2820521107>3.0.CO;2-6

M3 - Article

C2 - 6194873

AN - SCOPUS:0021042932

VL - 52

SP - 2011

EP - 2016

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 11

ER -